A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults

Trial Profile

A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs UB 421 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors United BioPharma
  • Most Recent Events

    • 09 May 2017 Status changed from planning to not yet recruiting.
    • 14 Dec 2016 New trial record
    • 07 Dec 2016 According to an United BioPharma media release, the joint drug is expected to submit the end of the second phase of the trial report and apply for clinical phase III trial to the US FDA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top